Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (28468)	3/4/1999 7:26:00 AM
From: JimmyD	Respond to of 32384

Henry: What's you're best guess on the time-line for the NDA and final approval of Targretin Capsules for CTCL. The information is probably somewhere among all these posts, but I don't have the time to sift though all the less-than intelligent posts that clutter this thread. Thanks in advance.

To: Henry Niman who wrote (28468)	3/4/1999 9:43:00 PM
From: ewolf	Read Replies (2) \| Respond to of 32384

Henry- This is a paragraph(pg.93 and 95) from the April Red Herring Magazine-- "David Moss of Phoenix Partners says that biotech venture firms are also looking more closely at investing in "spin-offs," or situations in which a public company allows certain assets to operate independently. Zach Hulsey, a managing director in Hambrecht and Quist's private placements division, says spin-offs are particularly attractive in the biotech industry because profitability is so elusive. In his view, spin-offs offer companies a way to clean up their balance sheets by removing expensive research projects from their bottom lines. For example, Ligand Pharmaceuticals, which develops drugs that regulate communications between cells, is reportedly courting VC investors for a spin-off that will develop and market a product it has devised.